CN116121128A - Bifidobacterium animalis subspecies lactis strain GOLDGUT-BB69 and application thereof - Google Patents
Bifidobacterium animalis subspecies lactis strain GOLDGUT-BB69 and application thereof Download PDFInfo
- Publication number
- CN116121128A CN116121128A CN202211660876.XA CN202211660876A CN116121128A CN 116121128 A CN116121128 A CN 116121128A CN 202211660876 A CN202211660876 A CN 202211660876A CN 116121128 A CN116121128 A CN 116121128A
- Authority
- CN
- China
- Prior art keywords
- product
- bifidobacterium animalis
- goldgut
- agent
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001134770 Bifidobacterium animalis Species 0.000 title claims abstract description 44
- 229940118852 bifidobacterium animalis Drugs 0.000 title claims abstract description 44
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 24
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 17
- 238000009629 microbiological culture Methods 0.000 claims abstract description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 12
- 230000003247 decreasing effect Effects 0.000 claims description 9
- 210000001072 colon Anatomy 0.000 claims description 8
- 230000009266 disease activity Effects 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 229940127557 pharmaceutical product Drugs 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 235000013365 dairy product Nutrition 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 241000186660 Lactobacillus Species 0.000 claims description 4
- 210000000068 Th17 cell Anatomy 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 210000003289 regulatory T cell Anatomy 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 3
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 206010009887 colitis Diseases 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 230000000181 anti-adherent effect Effects 0.000 claims description 2
- 239000002518 antifoaming agent Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000006184 cosolvent Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 239000004088 foaming agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 239000003961 penetration enhancing agent Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000003380 propellant Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000006096 absorbing agent Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000004321 preservation Methods 0.000 abstract description 12
- 244000005700 microbiome Species 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 19
- 239000000047 product Substances 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 13
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 12
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical group C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- 229940009289 bifidobacterium lactis Drugs 0.000 description 8
- 230000002550 fecal effect Effects 0.000 description 8
- 239000006041 probiotic Substances 0.000 description 8
- 235000018291 probiotics Nutrition 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 208000002551 irritable bowel syndrome Diseases 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 5
- 235000015243 ice cream Nutrition 0.000 description 5
- 235000020183 skimmed milk Nutrition 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 235000020247 cow milk Nutrition 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 229920003045 dextran sodium sulfate Polymers 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 4
- 229960004963 mesalazine Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000004579 body weight change Effects 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000003495 flagella Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000004682 mucosal barrier function Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000004953 colonic tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000009390 immune abnormality Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 229940068140 lactobacillus bifidus Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/366—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
- A23G9/36—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G9/363—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Agronomy & Crop Science (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to the field of microorganisms, in particular to a bifidobacterium animalis subspecies lactis strain GOLDGUT-BB69 and application thereof. The invention provides a bifidobacterium animalis subspecies (Bifidobacterium animalis subsp.lactis) strain GOLDGUT-BB69, which is preserved in China general microbiological culture Collection center (CGMCC) No.26204, the preservation time is 2022, 12 months and 14 days, and the preservation address is: the institute of microbiology, national institute of sciences, no. 3, north chen west way 1, the region of korea, beijing, postal code 100101. The bifidobacterium animalis subspecies lactis goldbut-BB 69 can reduce or treat inflammatory bowel disease.
Description
Technical Field
The invention relates to the field of microorganisms, in particular to a bifidobacterium animalis subspecies lactis strain GOLDGUT-BB69 and application thereof.
Background
Inflammatory bowel disease (Inflammatory bowel disease, IBD) includes ulcerative colitis (Ulcerative colitis, UC) and Crohn's Disease (CD), chronic gastrointestinal disease mediated by a variety of dysfunctional immune responses, as a result of interactions of factors such as environmental, genetic and immunomodulation.
The intestinal tract is a complex micro-ecological system and is one of the largest immune organs of the human body. The interaction between the intestinal micro-ecological environment and the host determines key physiological processes of human metabolism, including inflammatory response, metabolic function, and disease susceptibility and pathogenesis. Over the past decade, a number of clinical studies have shown that inflammation alters the intestinal micro-ecological environment and its metabolites, and that the affected intestinal micro-ecological environment in turn stimulates immune responses and metabolic activity, thus leading to chronic inflammation and ultimately chronic disease. Dysbiosis in the gut is a potentially relevant mechanism and major feature of IBD pathogenesis, as inflammation may progress toward cancer if left uncontrolled.
Probiotics are active microorganisms beneficial to a host, which are planted in a human body to change the flora composition of a certain part, and are various and common in species such as bifidobacteria, lactobacillus and the like. Probiotics alleviate IBD inflammation mainly by three means: (1) modulation of intestinal flora: the probiotics inhibit pathogenic bacteria activity by competing with pathogenic bacteria for nutrients or attachment sites, or generate antibacterial substances to directly inhibit the growth of pathogenic bacteria; (2) enhancing intestinal mucosal barrier function: probiotics enhance mucosal barrier function by promoting secretion of colonic tissue mucin and expression of MUC2 genes, and also maintain the integrity of mucosal barrier by reducing apoptosis of intestinal epithelial cells; (3) modulating mucosal immune responses: probiotics such as bifidobacteria and lactobacillus selectively inhibit various ways such as NF-kB activation of intestinal mucosa epithelial cells, regulate expression of inflammatory factors, reduce accumulation of inflammatory cells, inhibit inflammatory reaction and enhance mucosa immune defense function by regulating functions of dendritic cells. In summary, probiotics alleviate IBD symptoms by restoring intestinal flora diversity and mediating immune responses in a variety of ways, and are one of the potential therapeutic ways of IBD.
Disclosure of Invention
Therefore, the technical problem to be solved by the invention is to provide the bifidobacterium animalis subspecies lactis strain GOLDGUT-BB69 and the application thereof.
For this purpose, the invention provides the following technical scheme:
a bifidobacterium animalis subspecies (Bifidobacterium animalis subsp.lactis) strain GOLDGUT-BB69 is preserved in China general microbiological culture Collection center (CGMCC) No.26204, the preservation time is 2022, 12 months and 14 days, and the preservation address is: the institute of microbiology, national institute of sciences, no. 3, north chen west way 1, the region of korea, beijing, postal code 100101.
The bifidobacterium animalis subspecies lactis strain GOLDGUT-BB69 has the following biological characteristics: gram positive bacteria, no flagellum, no movement, no spore formation and obligate anaerobism; the polymorphobacillus has smooth colony and complete edge, and is milky white, shiny and soft. The optimal growth temperature is 37-41 ℃; the optimal pH value is 6.5-7.0.
The bifidobacterium animalis subspecies lactis strain GOLDGUT-BB69 has good tolerance to gastrointestinal digestive juice, and can enter human intestinal tracts in a living state after being digested in artificial gastric juice with the pH value of 2.5 for 3 hours and then continuously digested in artificial intestinal juice with the pH value of 8.0 for 8 hours, wherein the survival rate is 91.31 percent.
A product containing said bifidobacterium animalis subspecies lactobacillus strain GOLDGUT-BB 69.
Optionally, the product comprises a biologic, food or pharmaceutical product.
Alternatively, the biological product comprises a microbial agent, a subcultured offspring, a mutant or a starter of the bifidobacterium animalis subspecies lactis strain GOLDGUT-BB 69.
Optionally, the food comprises a solid beverage, a milk beverage, a pressed candy, a bean product, a dairy product or a fruit and vegetable product;
optionally, the food comprises a health food.
Optionally, the pharmaceutical product further comprises a pharmaceutical adjuvant, wherein the pharmaceutical adjuvant comprises at least one of a solvent, a propellant, a solubilizer, a cosolvent, an emulsifier, a colorant, an adhesive, a disintegrant, a filler, a lubricant, a wetting agent, an osmotic pressure regulator, a stabilizer, a glidant, a flavoring agent, a preservative, a suspending agent, a coating material, a fragrance, an anti-adhesive agent, an integrating agent, a permeation enhancer, a pH regulator, a buffer, a plasticizer, a surfactant, a foaming agent, an antifoaming agent, a thickener, an inclusion agent, a humectant, an absorbent, a diluent, a flocculant, a deflocculant, a filter aid, and a release retardant;
optionally, the pharmaceutical excipients comprise at least one of microcrystalline cellulose, hydroxypropyl methylcellulose and lecithin;
optionally, the dosage form of the medicine comprises granules, capsules, tablets, pills or oral liquid.
Optionally, the viable count of the bifidobacterium animalis subspecies lactis strain GOLDGUT-BB69 in the product is not less than 1 multiplied by 10 6 CFU/mL or 1X 10 6 CFU/g。
The use of said bifidobacterium animalis subspecies lactis strain GOLDGUT-BB69 or said product in the preparation of a product for reducing or treating inflammatory bowel disease.
Optionally, the uses include decreasing disease activity index score, decreasing colon weight/length ratio, inhibiting IL-17+ T cell numbers, increasing cd4+cd25+foxp3+ T cell numbers, and/or modulating Th17/Treg cell balance to reduce or treat inflammatory bowel disease.
Optionally, the inflammatory bowel disease is colitis;
optionally, the product comprises a biologic, food or pharmaceutical product.
The technical scheme of the invention has the following advantages:
1. the invention provides a bifidobacterium animalis subspecies (Bifidobacterium animalis subsp.lactis) strain GOLDGUT-BB69, which is preserved in China general microbiological culture Collection center (CGMCC) No.26204, the preservation time is 2022, 12 months and 14 days, and the preservation address is: the Bifidobacterium animalis subspecies of the animals have good tolerance to gastrointestinal digestive juice and can enter human intestinal tracts in a living state. The bifidobacterium animalis subspecies can reduce the disease activity index score of colonitis mice, reduce the weight/length ratio of colon, inhibit the number of IL-17+T cells, increase the number of CD4+CD25+Foxp3+T cells, and/or regulate the balance of Th17/Treg cells, thereby achieving the aim of reducing or treating inflammatory bowel disease.
Further, the bifidobacterium animalis subspecies may be used in food products, pharmaceutical products or biological products, such as solid beverages, pressed candies, bean products, dairy products or fruit and vegetable products.
The bifidobacterium animalis subspecies (Bifidobacterium animalis subsp.lactis) strain GOLDGUT-BB69 is preserved in the China general microbiological culture Collection center (CGMCC) No.26204, the preservation time is 2022, 12 months and 14 days, and the preservation address is: the institute of microbiology, national institute of sciences, no. 3, north chen west way 1, the region of korea, beijing, postal code 100101.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are needed in the description of the embodiments or the prior art will be briefly described, and it is obvious that the drawings in the description below are some embodiments of the present invention, and other drawings can be obtained according to the drawings without inventive effort for a person skilled in the art.
FIG. 1 is a graph showing DAI score results for each group of mice in Experimental example 1 of the present invention; wherein, in the columnar results corresponding to the 7 th, 14 th or 21 th day, NC group, DSS group, BB group, MS group and BM group are sequentially corresponding from left to right;
FIG. 2 is the results of colon weight/length ratios for each group of mice in experimental example 1 of the present invention;
FIG. 3 shows the% IL-17+T cell results for each group of mice in Experimental example 1 of the present invention;
FIG. 4 is the% CD4+CD25+Foxp3+ T cell results for each group of mice in Experimental example 1 of the present invention;
FIG. 5 shows the Th17/Treg ratio results for each group of mice in Experimental example 1 of the present invention.
Detailed Description
The following examples are provided for a better understanding of the present invention and are not limited to the preferred embodiments described herein, but are not intended to limit the scope of the invention, any product which is the same or similar to the present invention, whether in light of the present teachings or in combination with other prior art features, falls within the scope of the present invention.
The specific experimental procedures or conditions are not noted in the examples and may be followed by the operations or conditions of conventional experimental procedures described in the literature in this field. The reagents or apparatus used were conventional reagent products commercially available without the manufacturer's knowledge.
In the following examples, the Bifidobacterium animalis subspecies (Bifidobacterium animalis subsp.lactis) strain GOLDGUT-BB69 was deposited at China general microbiological culture Collection center (CGMCC) No.26204, with a deposit time of 2022, 12 months and 14 days, and a deposit address: the institute of microbiology, national institute of sciences, no. 3, north chen west way 1, the region of korea, beijing, postal code 100101.
EXAMPLE 1 screening, identification, observation and preservation of Bifidobacterium animalis subspecies Lactobacter GOLDGUT-BB69
Bacteria were isolated by dilution coating. After the fecal sample is oscillated, the fecal sample is absorbed into 0.5mL to 4.5mL of sterilized PBS, the ten-fold dilution method is used for gradient dilution, and 200 mu L of 10-3 and 10-4 dilutions are respectively absorbed and respectively coated in RCM solid culture medium. Anaerobic culture at 37deg.C for 72 hr to form colony; picking a colony by an inoculating loop, inoculating the colony into RCM liquid culture solution, and performing anaerobic culture at 37 ℃ for 72 hours; after the strain grows well, inoculating the strain into an RCM agar medium again by using an inoculating loop streak, culturing for 72 hours at 37 ℃, observing and recording colony morphology and gram staining cell morphology characteristics, and performing gram positive and catalase tests to isolate the strain which is negative in the tests, wherein the strain has the following biological characteristics: gram positive bacteria, no flagellum, no movement, no spore formation and obligate anaerobism; the polymorphobacillus has smooth colony and complete edge, and is milky white, shiny and soft. The optimal growth temperature is 37-41 ℃; the optimal pH value is 6.5-7.0. The strain was further purified and cultured, and was subjected to low-temperature preservation.
Bacterial DNA is extracted by adopting a root DNA extraction kit, and the 16S rRNA amplification and sequencing are carried out by utilizing a general primer of the 16S rRNA gene. The PCR amplified products were electrophoretically detected using 0.8% agarose gel, and the sequencing results were analyzed by Blast program for homology alignment with nucleic acid sequences of known bacteria in Gen Bank database. The strain is named as Bifidobacterium animalis subspecies (Bifidobacterium animalis subsp. Lactis) GOLDGUT-BB69 through preliminary identification, and is preserved in China general microbiological culture Collection center (CGMCC) No.26204 with the preservation time of 2022, 12 months and 14 days and the preservation address: the institute of microbiology, national institute of sciences, no. 3, north chen west way 1, the region of korea, beijing, postal code 100101.
Example 2
A food product for ameliorating inflammatory bowel disease comprising the following raw materials: a bifidobacterium animalis subspecies lactis (Bifidobacterium animalis subsp.lactis) strain GOLDGUT-BB69 and an edible material;
in the food, the viable count of the bifidobacterium animalis subspecies (Bifidobacterium animalis subsp. Lactis) strain GOLDGUT-BB69 is not less than 1×10 6 CFU/mL or 1X 10 6 CFU/g；
The edible material is fluid dairy (cow's milk, fluid cow's milk), milk powder, ice cream, cheese or cheese, in this example cow's milk is selected.
The above-mentioned method for preparing a food for improving inflammatory bowel disease, comprising: the method comprises the steps of uniformly mixing a skim milk culture solution of bifidobacterium animalis subspecies GOLDGUT-BB69 with cow milk components subjected to sterilization concentrated acid, and performing vacuum freeze sublimation drying to obtain the bifidobacterium animalis subspecies milk powder which has excellent effect on improving inflammatory bowel diseases.
Example 3
A preparation method of an animal bifidobacterium lactis ice cream comprises obtaining ice cream by conventional method, adding the animal bifidobacterium lactis powder prepared in example 2 before subpackaging, and stirring uniformly to obtain the animal bifidobacterium lactis ice cream. In the bifidobacterium animalis subspecies lactis ice cream, the viable count of the bifidobacterium animalis subspecies lactis GOLDGUT-BB69 is not less than 1 multiplied by 10 6 CFU/mL or 1X 10 6 CFU/g has good effect on improving inflammatory bowel disease.
Example 4
A method for preparing animal bifidobacterium subspecies lactis fermented milk, comprising the following steps:
the concentrated skim milk or skim milk powder-reinforced skim milk is used to mixSterilizing at 98deg.C for 40 min, cooling to 35deg.C, and adding 4% (w/v) of the Lactobacillus bifidus subspecies of GOLDGUT-BB69 starter (viable count 1×10) 7 CFU/g), and culturing at 35deg.C for 24 hr for 2% acidity, wherein the viable count of the animal bifidobacterium lactis subspecies GOLDGUT-BB69 is not less than 1×10 6 CFU/mL or 1X 10 6 CFU/g. The animal bifidobacterium subspecies lactis fermented milk is obtained, and has good effect on improving inflammatory bowel disease.
Example 5
A preparation method of a bifidobacterium animalis subspecies lactis capsule comprises the steps of culturing bifidobacterium animalis subspecies GOLDGUT-BB69 with a liquid culture solution, collecting and washing thalli, adding medicinal auxiliary materials, drying to prepare active fungus powder, preparing a capsule material by using gelatin, using PVP as a bottom coating, using beeswax for outer coating, and using the capsule for encapsulation to obtain the bifidobacterium animalis subspecies lactis capsule. In the bifidobacterium animalis subspecies lactis capsule, the viable count of the bifidobacterium animalis subspecies lactis GOLDGUT-BB69 is not less than 1 multiplied by 10 6 CFU/mL or 1X 10 6 CFU/g。
Example 6
A preparation method of animal bifidobacterium lactis subspecies fermented fruit and vegetable juice comprises the following steps:
firstly, 50 kg of carrots are taken, and sterile fruit and vegetable juice is obtained through the steps of sorting, cleaning, peeling, cutting, blanching, juice squeezing, pulping, batching, homogenizing and sterilizing.
Activating and expanding culture of animal Bifidobacterium lactis GOLDGUT-BB69, inoculating to sterile fruit and vegetable juice, fermenting, sampling and detecting, cooling, and aseptically packaging to obtain fermented fruit and vegetable juice, wherein the viable count of animal Bifidobacterium lactis GOLDGUT-BB69 is not less than 1×10 6 CFU/mL or 1X 10 6 CFU/g has good effect on improving inflammatory bowel disease.
Experimental example
Experimental animals: 40 male SPF grade C57BL/6J mice (purchased from Fukang Biotechnology Co., ltd., beijing) were purchased and kept in the inner Mongolian agricultural university dairy biotechnology and engineering education department key laboratory, and were subjected to indoor 12h illumination and darkness replacement. After one week of adaptive feeding, the mice were pre-fed for 1 week and the experiment was performed.
Experimental grouping: the animals were randomly divided into a normal group (NC group), a model group (DSS group), a probiotic intervention group (BB group), a positive drug group (MS group), and a bacterial drug combination group (BM group), 8 animals each.
The experimental method comprises the following steps: except for NC groups, each group was given 2.3% (w/v) aqueous sodium dextran sulfate (dextran sodium sulfate, DSS) for 7 days, and was changed to 0.8% (w/v) DSS aqueous solution on day 8, and the mice were dosed to 21 days with free water. From day 0 onwards, mice in BB group were given 0.2ml (4X 10) of GOLDGUT-BB69 broth 9 CFU/d) gastric lavage treatment, MS mice were given 0.2ml of 5-aminosalicylic acid solution (5-aminosalicylic acid 100mg/kg (body weight) daily), and BM mice were given the probiotic GOLDGUT-BB69 (GOLDGUT-BB 69 bacteria solution 0.2ml (4×10) daily) 9 CFU/d)) and 5-aminosalicylic acid (0.2 mL administered daily at a dose of 100mg/kg (body weight) of 5-aminosalicylic acid) were subjected to intragastric treatment, NC group and DSS group were subjected to intragastric treatment of 0.2mL per day with a period of 21 days for intervention. Throughout the experiment, the body weight and fecal status of the mice were recorded daily, the mice were free to ingest and drink water daily, the mice were sacrificed on day 21 and sampled for subsequent analysis.
Preparing bacterial liquid: culturing Bifidobacterium animalis subspecies of GOLDGUT-BB69 in liquid culture medium (commercially available product) at 37deg.C for 24 hr, centrifuging to collect thallus, adding 10% (w/v) sterilized skim milk into thallus, mixing, vacuum freeze drying to obtain lyophilized powder with viable count of Bifidobacterium animalis subspecies of GOLDGUT-BB69 of > 2×10 11 CFU/g. And then weighing the freeze-dried powder according to the administration dosage, and dissolving the freeze-dried powder in normal saline to prepare the medicine.
TABLE 1 liquid Medium composition
Experimental detection and results:
(1) Disease Activity index (Disease activity index, DAI) scoring
Disease activity index (Disease activity index, DAI) the mice were comprehensively evaluated for their rate of body weight change, fecal trait and fecal occult blood status, i.e., DAI score = rate of body weight change score + fecal trait score + fecal occult blood score. Specific scoring criteria are as follows: body weight change rate score: 0 = 0% -weight gain; 1 = 0% < weight change rate < 5%;2 = -5% < weight change rate +.10%; 3 = -10% < weight change rate +.15%; 4=rate of change of body weight > -15%. Stool trait scores; 0 = normal faeces; 1 = wet feces; 2 = loose stool; 3 = non-formed faeces. Fecal occult blood score: 4=0s < purple time < 10s; 3=10s < purple time < 30s; 2=30s < the time to change purple is less than or equal to 60s;1 = 60s < the time to change violet is less than or equal to 120s;0 = time to violet >120s.
The mice in each group were scored for disease activity index in the form of "mean ± standard deviation" (Means ± s.d.), and were analyzed for difference significance by t-test (student's t-test) analysis, as shown in fig. 1, and at day 7, the DAI scores in the remaining groups were significantly increased (P < 0.0001) compared to NC groups, mice were significantly less active, significantly less weight-bearing, were not shaped, and were individually bloody stool, indicating successful induction of an animal model of inflammatory bowel disease; on days 14 and 21, the BB group DAI score was significantly reduced (P < 0.05) compared to the DSS group. On day 21, there was no significant difference in DAI scores compared to the MS group, indicating no significant difference in bacterial and drug effects.
(2) Colon weight/length ratio
On day 21, colon tissue was collected from the anus to the distal cecum of each group of mice, the colon length was measured, and the weight thereof was weighed, and the data were processed in the manner of "mean ± standard deviation" (Means ± s.d.), and differential significance analysis was performed using a t-test (student's t-test) analysis. The results are shown in figure 2, and compared with the DSS group, the BB group can obviously reduce the ratio of colon weight (gram)/length (cm) (P < 0.05), which shows that the bifidobacterium lactis subspecies GOLDGUT-BB69 of the animal can effectively relieve colon inflammation and eliminate edema.
(3) Th17/Treg ratio
On day 21, the mouse spleen was stripped in pre-chilled PBS, gently ground in a cell sieve, rinsed with a volume of PBS, and spleen milling solution was collected. Adding the mouse spleen lymphocyte separating liquid with the same volume, mixing and centrifuging, and sucking the white membrane layer to obtain the mouse spleen mononuclear cells. Centrifugation and incubation were continued for cell stimulation culture. After 4h transfer to flow-through coupon, centrifuge to discard supernatant, add fixative (from Becton Dickinson and Company), membrane breaker (from Becton Dickinson and Company), fluorescent dye (from Becton Dickinson and Company) respectively in sequence. After incubation and resuspension, the detection is carried out on a machine.
As shown in fig. 3, the number of IL-17+t cells in NC group was significantly reduced (P < 0.05), the numbers of IL-17+t cells in BB group and MS group were significantly reduced (P < 0.01), and the numbers of IL-17+t cells in BM group were significantly reduced (P < 0.05) compared to DSS group, indicating that the bifidobacterium animalis subspecies goldbut-BB 69 of the present invention can significantly inhibit the release of pro-inflammatory cytokines.
As shown in fig. 4, the number of cd4+cd25+foxp3+ T cells was increased in the NC group compared to the DSS group, the number of cd4+cd25+foxp3+ T cells was significantly increased in the BB group (P < 0.05), and the number of cd4+cd25+foxp3+ T cells was significantly decreased in the MS group compared to the BB group (P < 0.05). It was demonstrated that the bifidobacterium animalis subspecies goldbut-BB 69 of the present invention can significantly increase the number of cd4+cd25+foxp3+ T cells to suppress inflammatory responses.
As shown in fig. 5, the number of Treg cells in BB group was significantly increased, while the number of Th17 cells was significantly decreased, the Th17/Treg ratio was significantly decreased (P < 0.001), the Th17/Treg ratio in MS group was significantly decreased (P < 0.05), the Th17/Treg ratio in BM group was significantly decreased (P < 0.001), as compared with DSS group.
In conclusion, the bifidobacterium animalis subspecies of the invention GOLDGUT-BB69 has the effects of reducing immune abnormality induced by inflammatory bowel disease and further treating IBD by regulating the cell balance of Th17/Treg of mice, regulating the release level of proinflammatory cytokines and anti-inflammatory cytokines.
Experimental example 2 tolerance to gastrointestinal digestive juice
preparation of artificial gastric juice at pH 2.5: in sterilized PBS (containing 0.8% (w/v) NaCl,0.02% (w/v) KH 2 PO 4 ，0.115％(w/v)Na 2 HPO 4 pH 7.2) (100 ml) was added with 3.0g/L Pepsin (sigma) (0.3 g), and the pH was adjusted to 2.5 with 0.1mol/L HCl to prepare simulated gastric fluid, which was filtered through a 0.22 μm sterile filter to be sterilized;
preparation of artificial intestinal juice with pH of 8.0: in sterilized PBS (containing 0.8% (w/v) NaCl,0.02% (w/v) KH 2 PO 4 ，0.115％(w/v)Na 2 HPO 4 1.0g/L Trypsin (0.3 g) and 1.8% bovine Bile salt (1.8 g) are added into 100ml (pH 7.2), pH value is adjusted to 8.0 by 0.1mol/L NaOH, simulated artificial intestinal juice is prepared, and a 0.22 mu m sterile filter membrane is used for filtration and sterilization;
the experimental method comprises the following steps: the bifidobacterium animalis subspecies lactis strain GOLDGUT-BB69 bacterial liquid (the original strain is continuously subjected to subculture for 2 times in MRS culture medium, bacterial cells which are subjected to subculture for 2 times and are in growth stabilization period are collected by centrifugation (3000 g/7min/4 ℃), the bacterial cells are obtained by suspending the bacterial cells in 10mL of PBS after washing for 2 times by PBS) is added into artificial gastric juice with the pH of 2.5 according to the volume ratio of 1:9, then the bacterial cells are digested for 3 hours at the temperature of 37 ℃, 1mL of the bacterial-containing artificial gastric juice is transferred into 9mL of artificial intestinal juice with the pH of 8.0, then the bacterial cells are digested for 8 hours at the temperature of 37 ℃, and the survival rate is measured by counting by a flat plate counting method in 0 hour (which is started to be digested in artificial gastric juice with the pH of 8.0), and the measurement result is 91.31 percent.
It is apparent that the above examples are given by way of illustration only and are not limiting of the embodiments. Other variations or modifications of the above teachings will be apparent to those of ordinary skill in the art. It is not necessary here nor is it exhaustive of all embodiments. While still being apparent from variations or modifications that may be made by those skilled in the art are within the scope of the invention.
Claims (9)
1. A strain GOLDGUT-BB69 of Bifidobacterium animalis subspecies (Bifidobacterium animalis subsp. Lactis) is preserved in China general microbiological culture Collection center (CGMCC) No.26204.
2. A product comprising the bifidobacterium animalis subspecies lactis strain GOLDGUT-BB69 of claim 1.
3. The product of claim 2, wherein the product comprises a biologic, a food, or a pharmaceutical.
4. A product according to claim 3, characterized in that the biological product comprises a microbial agent, subcultured offspring, mutant strain or starter agent of bifidobacterium animalis subspecies lactis strain GOLDGUT-BB 69.
5. The product of claim 3 or 4, wherein the food product comprises a solid beverage, a dairy beverage, a pressed candy, a bean product, a dairy product, or a fruit and vegetable product;
optionally, the food comprises a health food.
6. The product of any one of claims 3-5, wherein the pharmaceutical product further comprises a pharmaceutical adjuvant comprising at least one of a solvent, a propellant, a solubilizing agent, a co-solvent, an emulsifier, a colorant, a binder, a disintegrant, a filler, a lubricant, a wetting agent, an osmotic pressure regulator, a stabilizer, a glidant, a flavoring agent, a preservative, a suspending agent, a coating material, a fragrance, an anti-adhesive agent, an integration agent, a permeation enhancer, a pH regulator, a buffer, a plasticizer, a surfactant, a foaming agent, an antifoaming agent, a thickener, a inclusion agent, a humectant, an absorber, a diluent, a flocculant, a deflocculant, a filter aid, and a release retardant;
optionally, the pharmaceutical excipients comprise at least one of microcrystalline cellulose, hydroxypropyl methylcellulose and lecithin;
optionally, the dosage form of the medicine comprises granules, capsules, tablets, pills or oral liquid.
7. The product according to any one of claims 3 to 6, wherein the viable count of the bifidobacterium animalis subspecies lactis strain GOLDGUT-BB69 is not less than 1X 10 6 CFU/mL or 1X 10 6 CFU/g。
8. Use of a bifidobacterium animalis subspecies lactobacillus strain GOLDGUT-BB69 or a product as defined in any of claims 2 to 7 for the manufacture of a product for reducing or treating inflammatory bowel disease.
9. The use of claim 8, comprising decreasing disease activity index score, decreasing colon weight/length ratio, inhibiting IL-17+ T cell numbers, increasing cd4+cd25+foxp3+ T cell numbers, and/or modulating Th17/Treg cell balance to reduce or treat inflammatory bowel disease;
optionally, the inflammatory bowel disease is colitis;
optionally, the product comprises a biologic, food or pharmaceutical product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211660876.XA CN116121128B (en) | 2022-12-23 | 2022-12-23 | Bifidobacterium animalis subspecies lactis strain GOLDGUT-BB69 and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211660876.XA CN116121128B (en) | 2022-12-23 | 2022-12-23 | Bifidobacterium animalis subspecies lactis strain GOLDGUT-BB69 and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116121128A true CN116121128A (en) | 2023-05-16 |
| CN116121128B CN116121128B (en) | 2024-10-01 |
Family
ID=86302019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211660876.XA Active CN116121128B (en) | 2022-12-23 | 2022-12-23 | Bifidobacterium animalis subspecies lactis strain GOLDGUT-BB69 and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116121128B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116769654A (en) * | 2023-06-14 | 2023-09-19 | 内蒙古农业大学 | Bifidobacterium animalis subspecies lactis and application thereof |
| CN117736911A (en) * | 2023-11-28 | 2024-03-22 | 金华银河生物科技有限公司 | Bifidobacterium breve B-169 and application thereof in reducing blood pressure |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107723257A (en) * | 2017-09-20 | 2018-02-23 | 深圳市晨光乳业有限公司 | A kind of animal bifidobacteria and its food compositions |
| CN113430133A (en) * | 2021-06-24 | 2021-09-24 | 微康益生菌(苏州)股份有限公司 | Composite probiotics capable of relieving ulcerative colitis, preparation method and application thereof |
| CN114480229A (en) * | 2022-04-15 | 2022-05-13 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium animalis subsp lactis strain WKB148 and product and application thereof |
| WO2022133198A1 (en) * | 2020-12-18 | 2022-06-23 | The General Hospital Corporation | Probiotics compositions and method of using the same to enhance growth and social function in children |
| CN114681493A (en) * | 2020-12-31 | 2022-07-01 | 杭州远大生物制药有限公司 | Application of bifidobacterium animalis subsp lactis |
-
2022
- 2022-12-23 CN CN202211660876.XA patent/CN116121128B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107723257A (en) * | 2017-09-20 | 2018-02-23 | 深圳市晨光乳业有限公司 | A kind of animal bifidobacteria and its food compositions |
| WO2022133198A1 (en) * | 2020-12-18 | 2022-06-23 | The General Hospital Corporation | Probiotics compositions and method of using the same to enhance growth and social function in children |
| CN114681493A (en) * | 2020-12-31 | 2022-07-01 | 杭州远大生物制药有限公司 | Application of bifidobacterium animalis subsp lactis |
| CN113430133A (en) * | 2021-06-24 | 2021-09-24 | 微康益生菌(苏州)股份有限公司 | Composite probiotics capable of relieving ulcerative colitis, preparation method and application thereof |
| CN114480229A (en) * | 2022-04-15 | 2022-05-13 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium animalis subsp lactis strain WKB148 and product and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| WANG N等: "Alleviation Effects of Bifidobacterium animalis subsp. lactis XLTG11 on Dextran Sulfate Sodium-Induced Colitis in Mice", 《MICROORGANISMS》, 3 October 2021 (2021-10-03) * |
| 马岩等: "动物双歧杆菌乳亚种XLTG11对葡聚糖硫酸钠诱导小鼠溃疡性结肠炎的缓解作用", 《食品科学》, 23 December 2021 (2021-12-23) * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116769654A (en) * | 2023-06-14 | 2023-09-19 | 内蒙古农业大学 | Bifidobacterium animalis subspecies lactis and application thereof |
| CN117736911A (en) * | 2023-11-28 | 2024-03-22 | 金华银河生物科技有限公司 | Bifidobacterium breve B-169 and application thereof in reducing blood pressure |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116121128B (en) | 2024-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116121128B (en) | Bifidobacterium animalis subspecies lactis strain GOLDGUT-BB69 and application thereof | |
| CN100552016C (en) | The bifidus bacillus that is used for the treatment of inflammatory diseases | |
| CN110964655B (en) | Bifidobacterium lactis BL-99 and application thereof | |
| CN113293113B (en) | Bifidobacterium longum MI-186 and application thereof | |
| CN114376234A (en) | Activated bifidobacteria and methods of use thereof | |
| CN116024131B (en) | Lactobacillus plantarum strain GOLDGUT-LP101 and application thereof | |
| CN107164263A (en) | A kind of adjustable function of intestinal canal, the lactobacillus fermenti HY01 for preventing colitis and application thereof | |
| CN106389479B (en) | Application of bacillus coagulans in preparation of preparation for preventing or treating autism | |
| CN106604736A (en) | Use of lactobacillus paracasei for promoting recovery of the intestinal microbiota diversity after dysbiosis | |
| CN114480229A (en) | Bifidobacterium animalis subsp lactis strain WKB148 and product and application thereof | |
| CN116064326B (en) | Bifidobacterium animalis subspecies GBW8051 capable of relieving depression and application thereof | |
| CN109312297A (en) | For treating the Lactobacillus casei of obesity and associated metabolic disease | |
| CN106659747A (en) | Use of lactobacillus rhamnosus for promoting recovery of the intestinal microbiota diversity after dysbiosis | |
| CN112218646A (en) | Composition and application thereof | |
| RU2580002C1 (en) | Method of producing autoprobiotic containing living bifidus bacteria and lactic acid bacilli | |
| CN116121154B (en) | Leuconostoc lactis and application thereof | |
| CN108295096B (en) | Application of bacterial strain in preparation for preventing and treating mycotic and bacterial vaginosis | |
| CN107854495B (en) | Application of bacillus coagulans in preparation of preparation for reducing hematuria | |
| JP2024532769A (en) | Postbiotics | |
| CN114164158A (en) | Bifidobacterium strain ZK-77 for inhibiting pathogenic bacteria, relieving inflammation, and balancing flora | |
| CN106389478B (en) | Application of bacteroides fragilis in treatment and/or prevention of obesity or diabetes | |
| CN113151070B (en) | Lactobacillus fermentum capable of improving relative abundance of Guttiferae in intestinal tract | |
| CN116790431A (en) | Bifidobacterium animalis subspecies lactis and microbial agent capable of relieving constipation and diarrhea and application thereof | |
| CN114164157B (en) | Lactobacillus salivarius strain ZK-88 for inhibiting inflammation, relieving swelling and aching of gum, and improving oral flora balance | |
| CN107083342B (en) | Probiotic symbiont, culture method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |